<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30327858</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1432-1963</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>39</Volume>                    <Issue>6</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                    </PubDate>                </JournalIssue>                <Title>Der Pathologe</Title>                <ISOAbbreviation>Pathologe</ISOAbbreviation>            </Journal>            <ArticleTitle>[Standardized determination of tumor-infiltrating lymphocytes in breast cancer : A prognostic marker for histological diagnosis].</ArticleTitle>            <Pagination>                <MedlinePgn>520-531</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00292-018-0530-y</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Tumor-infiltrating lymphocytes (TILs) have been identified as prognostic parameter in breast cancer.</AbstractText>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this review article is to provide an overview on the clinical and analytical validation of TILs in breast cancer.</AbstractText>                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Summary of international guidelines of the TIL working group as well as clinical and translational studies.</AbstractText>                <AbstractText Label="RESULTS, CONCLUSIONS" NlmCategory="UNASSIGNED">Breast carcinomas with a high TIL level have an improved response to neoadjuvant chemotherapy. Triple-negative and HER2-positive carcinomas with increased TIL levels have improved survival. TILs are a new prognostic biomarker for routine histopathological diagnosis.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Denkert</LastName>                    <ForeName>C</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Institut für Pathologie der Charité, Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland. carsten.denkert@charite.de.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Deutsches Konsortium für Translationale Krebsforschung (DKTK), Standort Berlin, Berlin, Deutschland. carsten.denkert@charite.de.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Loibl</LastName>                    <ForeName>S</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>German Breast Group, Neu-Isenburg, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Budczies</LastName>                    <ForeName>J</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Institut für Pathologie der Charité, Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institut für Pathologie, Universität Heidelberg, Heidelberg, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wienert</LastName>                    <ForeName>S</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Institut für Pathologie der Charité, Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>VMscope GmbH, Berlin, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Klauschen</LastName>                    <ForeName>F</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Institut für Pathologie der Charité, Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>ger</Language>            <PublicationTypeList>                <PublicationType UI="D004740">English Abstract</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <VernacularTitle>Standardisierte Bestimmung tumorinfiltrierender Lymphozyten beim Mammakarzinom : Ein prognostischer Marker für die histologische Diagnostik.</VernacularTitle>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Pathologe</MedlineTA>            <NlmUniqueID>8006541</NlmUniqueID>            <ISSNLinking>0172-8113</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2015 Feb;26(2):259-71</RefSource>                <PMID Version="1">25214542</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA Oncol. 2016 Jan;2(1):56-64</RefSource>                <PMID Version="1">26469139</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25</RefSource>                <PMID Version="1">29024776</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2018 Jan;19(1):40-50</RefSource>                <PMID Version="1">29233559</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2017 Jan;18(1):52-62</RefSource>                <PMID Version="1">27964843</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Immunol. 2017 Feb;17(2):97-111</RefSource>                <PMID Version="1">27748397</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pathol Clin Res. 2015 Jul 20;1(4):225-38</RefSource>                <PMID Version="1">27499907</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Anat Pathol. 2017 Sep;24(5):235-251</RefSource>                <PMID Version="1">28777142</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Pathol Lab Med. 1993 Oct;117(10):1005-8</RefSource>                <PMID Version="1">8215820</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Diagn Pathol. 2018 Aug;35:77-79</RefSource>                <PMID Version="1">29886396</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2017 Aug 1;28(8):1700-1712</RefSource>                <PMID Version="1">28838210</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>NPJ Breast Cancer. 2016 May 18;2:16014</RefSource>                <PMID Version="1">28721378</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64</RefSource>                <PMID Version="1">21960707</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA Oncol. 2015 Jul;1(4):448-54</RefSource>                <PMID Version="1">26181252</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2018 May 18;:null</RefSource>                <PMID Version="1">29788230</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2013 Dec 18;105(24):1897-906</RefSource>                <PMID Version="1">24203987</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2018 Feb 1;110(2):null</RefSource>                <PMID Version="1">28859291</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2015 Aug;26(8):1698-704</RefSource>                <PMID Version="1">25995301</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Anat Pathol. 2017 Nov;24(6):311-335</RefSource>                <PMID Version="1">28777143</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2013 Nov;24(11):2786-93</RefSource>                <PMID Version="1">23970015</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2015 Aug 15;21(16):3651-7</RefSource>                <PMID Version="1">25501130</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Death Differ. 2018 Mar;25(3):486-541</RefSource>                <PMID Version="1">29362479</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Surg Oncol. 2016 Jul;23(7):2242-8</RefSource>                <PMID Version="1">26965699</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genome Biol. 2016 Oct 20;17(1):218</RefSource>                <PMID Version="1">27765066</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2012 Apr 18;486(7403):346-52</RefSource>                <PMID Version="1">22522925</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2013 May 15;19(10):2775-86</RefSource>                <PMID Version="1">23493347</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mod Pathol. 2016 Oct;29(10):1155-64</RefSource>                <PMID Version="1">27363491</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2010 Jan 1;28(1):105-13</RefSource>                <PMID Version="1">19917869</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Oncol. 2018 Jan;57(1):90-94</RefSource>                <PMID Version="1">29168428</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2018 May 26;391(10135):2128-2139</RefSource>                <PMID Version="1">29754777</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2014 Aug;25(8):1544-50</RefSource>                <PMID Version="1">24608200</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2013 Mar 1;31(7):860-7</RefSource>                <PMID Version="1">23341518</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2014 Sep 20;32(27):2959-66</RefSource>                <PMID Version="1">25071121</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Indian J Pathol Microbiol. 2018 Apr-Jun;61(2):181-186</RefSource>                <PMID Version="1">29676353</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2015 Mar 20;33(9):983-91</RefSource>                <PMID Version="1">25534375</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 1949 Jul;2(4):635-42</RefSource>                <PMID Version="1">18144972</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Biomarkers</Keyword>            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">Immune infiltrate</Keyword>            <Keyword MajorTopicYN="N">Neoadjuvant therapy</Keyword>            <Keyword MajorTopicYN="N">Prognosis</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30327858</ArticleId>            <ArticleId IdType="doi">10.1007/s00292-018-0530-y</ArticleId>            <ArticleId IdType="pii">10.1007/s00292-018-0530-y</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>